Skip to main content
SpringerLink
Log in

Herb—Drug Interaction of Quercetin on the Pharmacokinetics of Losartan in Rats: A High-Performance Thin-L ayer Chromatography Study

  • Original Research Papers
  • Published:
JPC – Journal of Planar Chromatography – Modern TLC Aims and scope Submit manuscript

Summary

Losartan potassium (LOS), used in the treatment of hypertension, is metabolized primarily by cytochrome P450. This study investigates the effect of quercetin (QU), a CYP3A4 inducer, on the pharmacokinetics of LOS in rats. A rapid, sensitive high-performance thin-layer chromatography (HPTLC) method was developed and validated for the bioanalysis of losartan using olmesartan as internal standard (IS). The salting-out assisted liquid—liquid extraction (SALLE) employing acetonitrile and MgCl2 gave high recovery of LOS (>90%). HPTLC separation, achieved on silica gel 60 F254 plates employing toluene—ethyl acetate—acetone—formic acid (4:4:1:0.5 V/V) as the mobile phase, with densitometric analysis at 240 nm, gave good linearity (50–1200 ng mL-1) with high intra-day and i nter-day precision. LOS in plasma samples was stable when stored under different stability conditions. The pharmacokinetics of LOS was found to be significantly altered when co-administered with QU: C max = 809.8 ± 4.1 at 40 min (t max) to C max = 1124.8 ± 86.6 ng mL-1 at 120 min (t max). This study indicates the chances of herb—drug interaction when LOS is co-administered with QU, leading to its increased bioavailability, potentiating its side effect/toxic manifestation. As QU is abundantly present in herbs and dietary food, patients of LOS therapy need to be cautious while concurrently consuming herbal preparations containing QU. This study also demonstrates the utility of HPTLC as an effective tool for pharmacokinetics study for the estimation of herb—drug interactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. S. Brantley, A. Argikar, Y.S. Lin, S. Nagar, M.F. Paine, Herb—drug interactions: challenges and opportunities for improved predictions, Drug Metab. Dispos. 42 (2014) 301–317.

    PubMed  Google Scholar 

  2. A. Fugh-Berman, E. Ernst, Herb—drug interactions: review and assessment of report reliability, Br. J. Clin. Pharmacol. 52 (2001) 587–595.

    CAS  Google Scholar 

  3. S. Bromfield, P. Muntner, High blood pressure: the leading global burden of disease risk factor and the need for worldwide prevention programs, Curr. Hypertens. Rep. 15 (2013) 134–136.

    PubMed  Google Scholar 

  4. J. Daubney, P.L. Bonner, A.J. Hargreaves, J.M. Dickenson, Cardioprotective and cardiotoxic effects of quercetin and two of its in vivo metabolites on differentiated H9c2 cardiomyocytes, Basic Clin. Pharmacol. Toxicol. 116 (2015) 96–109.

    Article  CAS  Google Scholar 

  5. A.A. Izzo, G. Di Carlo, F. Borrelli, E. Ernst, Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction, Int. J. Cardiol. 98 (2005) 1–14.

    PubMed  Google Scholar 

  6. D.A. Sica, T.W. Gehr, S. Ghosh, Clinical pharmacokinetics of losartan, Clin. Pharmacokinet. 44 (2005) 797–814.

    Article  CAS  Google Scholar 

  7. S. Liu, F.L. Bu, C.M. Wei, G.Y. Yuan, B.J. Wang, R.C. Guo, Pharmacokinetics of hydrochlorothiazide, losartan and E3174 after oral doses of losartan and losartan/hydrochlorothiazide in healthy Chinese male volunteers, Pharmacol. Pharm. 3 (2012) 7–14.

    CAS  Google Scholar 

  8. M.W. Lo, M.R. Goldberg, J.B. McCrea, H. Lu, C.I. Furtek, T.D. Bjornsson, Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans, Clin. Pharmacol. Ther. 58 (1995) 641–649.

    CAS  PubMed  Google Scholar 

  9. R. Shanmugam, K. Gowthamarajan, D.L. Priyanka, K. Madhuri, V.V. Karri Narayanareddy, Bioanalytical method development and validation for herbal quercetin in nano formulation by RPU-FLC in rabbit plasm, J. Bioequiv. Availab. 5 (2013) 191–196.

    Google Scholar 

  10. S.N. Umathe, P.V. Dixit, K.U. Bansod, M.M. Wanjari, Quercetin pre-treatment increases the bioavailability of pioglitazone in rats: involvement of CYP3A inhibition, Biochem. Pharmacol. 75 (2008) 1670–1676.

    CAS  Google Scholar 

  11. E.R. Lee, G.H. Kang, S.G. Cho, Effect of flavonoids on human health: old subjects but new challenges, Recent Pat. Biotechnol. 1 (2007) 139–150.

    CAS  Google Scholar 

  12. K.J. Gohil, J.A. Patel, Herb–drug interactions: a review and study based on assessment of clinical case reports in literature, Indian J. Pharmacol. 39 (2007) 129–139.

    Google Scholar 

  13. M.C. Morand, C. D.O. Texier, F. Regerat, C. Remesy, Bioavailability of rutin and quercetin in rats, FEBS Lett. 409 (1997) 12–16.

    PubMed  Google Scholar 

  14. H.J. Shah, M.L. Kundlik, N.K. Patel, G. Subbaiah, D.M. Patel, B.N. Suhagia, C.N. Patel, Rapid determination of losartan and losartan acid in human plasma by multiplexed LC–MS/MS, J. Sep. Sci. 20 (2009) 3388–3394.

    Google Scholar 

  15. A. Kumar, M. Debnath, J.V.L.N. Seshagiri Rao, G. Sankar, New validated stability indicating RP-HPLC bioanalytical method development and validation for simultaneous estimation of hydrochlorothiazide, ramipril and losartan in human plasma by using PDA detector, Pharm. Anal. Acta 6 (2017) 1–8.

    Google Scholar 

  16. V.K. Karra, N.R. Pilli, J.K. Inamadugu, J.V.L.N. Seshagiri Rao, Simultaneous determination of losartan, losartan acid and amlodipine in human plasma by LC–MS/MS and its application to a human pharmacokinetic study, Pharm Methods. 3 (2012) 18–25.

    PubMed  Google Scholar 

  17. D. Goswami, A. Kumar, A.H. Khuroo, T. Monif, N.R. Thudi, V.K. Shrivastav, S.K. Dubey, A.K. Shingla, M. Prakash, S. Mehra, Pharmacokinetic estimation of losartan, losartan carboxylic acid and hydrochlorothiazide in human plasma by LC/MS/MS validated method, Clin. Res. Regul. Aff. 25 (2008) 235–258.

    Google Scholar 

  18. M. Del Rosario Brunetto, Y. Contreras, S. Clavijo, D. Torres, Y. Delgado, F. Ovalles, C. Ayala, M. Gallignani, J.M. Estela, V.C. Martin, Determination of losartan, telmisartan, and valsartan by direct injection of human urine into a column-switching liquid chromatographic system with fluorescence, J. Pharm. Biomed. Anal. 50 (2009) 194–199.

    PubMed  Google Scholar 

  19. P.K. Yeung, A. Jamieson, G.J. Smith, D. Fice, P.T. Pollak, A validated RP-LC method for simultaneous determination of losartan potassium and amlodipine besilate in pharmaceutical preparations, Int. J. Pharm. 204 (2000)17–22.

    CAS  Google Scholar 

  20. S. Shivakumar, T. Sudhir, R. Mital, G. Devala Rao, S.V.S.G.B. Prasad, LC/MS/MS method for the simultaneous estimation of losartan potassium and irbesartan in rat plasma, Int. J. Pharm. Pharm. Sci. 1 (2009) 206–215.

    Google Scholar 

  21. S.K. Shetty, K.V. Surendranath, P. Radhakrishnanand, R.M. Borkar, P.S. Devrukhakar, J. Jogul, U.M. Tripathi, Quantitative application to a polypill by the development of stability indicating LC method for the simultaneous estimation of aspirin, atorvastatin, atenolol and losartan potassium, Am. J. Anal. Chem. 2 (2010) 59–69.

    Google Scholar 

  22. L. González, J.A. López, R.M. Alonso, R.M. Jiménez, Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection, J. Chromatogr. A 949 (2002) 49–60.

    PubMed  Google Scholar 

  23. D.L. Hertzog, J.F. McCafferty, X. Fang, R.J. Tyrrell, R.A. Reed, In vitro evidences for simvastatin and losartan potassium interaction and its in vivo implications, J. Pharm. Biomed. Anal. 30 (2002) 747–60.

    Article  CAS  Google Scholar 

  24. R.A. Stearns, P.K. Chakravarty, R. Chen, S.H. Chi, Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members, Drug Metab. Dispos. 23 (1995) 207–215.

    CAS  PubMed  Google Scholar 

  25. M. Selvadurai, S.N. Meyyanathan, Sensitive and accurate estimation of losartan potassium formulation by high-performance thin-layer chromatography, Pharm. Methods 2 (2011) 95–98.

    Article  Google Scholar 

  26. A.K Kolsure, B.B. Chavan, A.R. Chabukswar, B.S. Kuchekar, Development and validation of a HPTLC method for simultaneous estimation of atorvastatin calcium and losartan potassium in combined dosage form, Asian J. Biomed. Pharm. 4 (2014) 20–24.

    Google Scholar 

  27. R. Dubey, V.K. Bhusari, S.R. Dhaneshwar, Validated HPTLC method for simultaneous estimation of losartan potassium and metolazone in bulk drug and formulation, Pharm. Lett. 3 (2015) 334–342.

    Google Scholar 

  28. K.B Bodiwala, K. Mali, P. Patel, P.B. Prajapati, B.P. Marolia, G.G. Kalyankar, Estimation of losartan potassium and ramipril in their combined dosage form by validated HPTLC method, Eurasian J. Anal. Chem. 12 (2017) 167–177.

    CAS  Google Scholar 

  29. K.E. McCarthy, Q. Wang, E.W Tsai, R.E. Gilbert, D.P. Ip, M.A. Brooks, Determination of losartan and its degradates in COZAAR® tablets by reversed-phase high-performance thin-layer chromatography, J. Pharm. Biomed. Anal. 17 (1998) 671–677.

    CAS  Google Scholar 

  30. S.V. Shah, I.S. Rathod, B. Suhagai, S.S. Savale, Simultaneous determination of losartan and hydrochlorothiazide in combined dosage forms by first-derivative spectroscopy and high-performance thin-layer chromatography, J. AOAC Int. 84 (2001) 1715–1723.

    CAS  PubMed  Google Scholar 

  31. L.K. Santhana, S. Lakshmi, Simultaneous analysis of losartan potassium, amlodipine besylate, and hydrochlorothiazide in bulk and in tablets by high-performance thin-layer chromatography with UV–absorption densitometry, J. Anal. Methods Chem. 2012 (2012) 108281. Doi: 10.1155/2012/108281.

    Google Scholar 

  32. D. Tsvetkova, D. Obreshkova, Application of validated TLC–densitometric method for simultaneous identifi cation and determination of losartan potassium, telmisartan, and valsartan in tablets, J. Planar Chromatogr. 25 (2012) 326–330.

    CAS  Google Scholar 

  33. Guidance for Industry. Bioanalytical Method Validation, Centre for Drug Evaluation and Research (CDER), US Department of Health and Human Services, Food and Drug Administration, Rockville, MD, 2018.

  34. D.A Sica, T.W. Gehr, S. Ghosh, Clinical pharmacokinetics of losartan, Clin. Pharmacokinet. 44 (2005) 797–814.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Quality Assurance, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, India

    Shraddha Jadhao, Asha Thomas, Lata Kothapalli & Aaftab Shaikh

  2. Clinical Candidate Optimization Department, Advinus Therapeutics Ltd., Pune, India

    Amol Raje

  3. Department of Pharmacology, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, India

    Shatrughna Nagrik

Authors
  1. Shraddha Jadhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Asha Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amol Raje
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shatrughna Nagrik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lata Kothapalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aaftab Shaikh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Asha Thomas.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jadhao, S., Thomas, A., Raje, A. et al. Herb—Drug Interaction of Quercetin on the Pharmacokinetics of Losartan in Rats: A High-Performance Thin-L ayer Chromatography Study. JPC-J Planar Chromat 32, 401–409 (2019). https://doi.org/10.1556/1006.2019.32.5.8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1556/1006.2019.32.5.8

Key Words

Search

Navigation